Matthew E Korenberg
CIK 1649903 · CFO, Treasurer · last filed 2026-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LGND price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 200
LA JOLLA, CA 92037
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PVLA | CFO, Treasurer | 1,000 | $177.38 | $177.4K | $0 | 4 | 2026-06-16 |
| LFCR | Director | 69,967 | $6.38 | $446.4K | $0 | 3 | 2026-06-05 |
| LGND | President & COO | 50,777 | $314.10 | $15.95M | -$12.53M | 50 | 2024-09-24 |
| Qualigen Therapeutics, Inc. (QLGN) Delisted | Director | — | $3.21 | — | $0 | 2 | 2022-08-04 |
Recent Filings · Page 2 of 7
67 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-18 | LGND | Mixed | +2,560 | $226 | EDGAR |
| 2024-08-26 | LGND | Sell (S) | −18,858 | -$1.99M | EDGAR |
| 2024-08-22 | LGND | Notice (144) | −18,858 | -$1.98M | EDGAR |
| 2024-08-21 | LFCR | Grant (A) | +24,554 | $0 | EDGAR |
| 2024-08-13 | LGND | Sell (S) | −18,245 | -$1.80M | EDGAR |
| 2024-08-09 | LGND | Notice (144) | −18,245 | -$1.80M | EDGAR |
| 2024-07-02 | LGND | Other (J) | +350 | $21.2K | EDGAR |
| 2024-05-15 | LGND | Sell (S) | −17,598 | -$1.50M | EDGAR |
| 2024-05-15 | LGND | Notice (144/A) | −3,440 | -$290.8K | EDGAR |
| 2024-05-14 | LGND | Notice (144) | −14,158 | -$1.20M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.